Markers for the non-invasive diagnosis of mesothelioma: a systematic review by van der Bij, S et al.
Markers for the non-invasive diagnosis of mesothelioma:
a systematic review
S van der Bij*,1, E Schaake
2, H Koffijberg
1, JA Burgers
2, BAJM de Mol
3,4 and KGM Moons
1
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Stratenum 6.131, PO Box 85500, 3508 GA Utrecht,
The Netherlands;
2Department of Thoracic Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121 1066 CX,
Amsterdam, The Netherlands;
3Department of Cardiothoracic Surgery, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ,
The Netherlands;
4Department of Biomedical Engineering, Eindhoven University of Technology, Den Dolech 2, Eindhoven 5600 MB, The Netherlands
BACKGROUND: Numerous markers have been evaluated to facilitate the non-invasive diagnostic work-up of mesothelioma. The
purpose of this study was to conduct a structured review of the diagnostic performance of non-invasive marker tests for the
detection of mesothelioma in patients with suspected mesothelioma.
METHODS: Studies on the diagnostic accuracy of serum and cytological markers published till 31 December 2009, available in either
PUBMED or Embase, to detect or exclude the presence of mesothelioma were extracted. Study quality was assessed with use of the
Quadas criteria.
RESULTS: In total, 82 articles were included in this systemic review. Overall, quality of the incorporated studies to address our objective
was poor. The most frequently studied immunohistochemical markers for cytological analysis were EMA, Ber-Ep4, CEA, and
calretinin. The most frequently investigated serum marker was soluble mesothelin-related protein (SMRP). The markers CEA,
Ber-EP4, and calretinin were most valuable in discriminating mesothelioma from other malignant diseases. Markers EMA and SMRP
were most valuable in discriminating mesothelioma from non-malignant diseases. No marker performed well in discriminating
between mesothelioma and all other diseases.
CONCLUSION: Currently, there is only limited evidence to properly assess the value of non-invasive marker tests in the diagnosis of
mesothelioma. Studies were of limited value to address our objective and results showed considerable unexplained study
heterogeneity.
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The diagnosis of mesothelioma is not straightforward. The
symptoms are nonspecific, and only in experienced centres,
pleural fluid cytology is a reliable diagnostic tool. Hence, most
patients ultimately require invasive procedures such as core-needle
or open biopsy, or video-assisted thoracoscopy to facilitate
histological examination as ‘gold’ standard for diagnosis (Renshaw
et al, 1997; Fletcher and Clark, 2007; Fassina et al, 2008). However,
a biopsy may complicate subsequent disease management by
seeding tumor cells or may be unfeasible because of poor
condition of the patient. Therefore, it would be valuable to have
non-invasive diagnostic procedures that accurately confirm or
exclude the diagnosis of mesothelioma.
Accordingly, innumerable non-invasive markers have emerged,
based on the increasing understanding of the molecular and
biological pathways of mesothelioma, and studied in numerous
studies. These include many immunohistochemical markers that
have been tested for their property to establish the diagnosis of
mesothelioma on cytological grounds (Lyons-Boudreaux et al,
2008). Promising other tests are genetic markers and serum
markers such as soluble mesothelin-related protein (SMRP) and
megakaryocyte potentiating factor (Pass et al, 2005; Holloway et al,
2006; Scherpereel et al, 2006; Creaney et al, 2008).
However, estimated diagnostic accuracy of identical markers
varies widely between studies. Therefore, it remains unclear which
marker has a superior performance. Nevertheless, several markers
have already entered the market and are used in clinical practice.
In contrast, others disappeared after initial promising results. As a
result, current diagnostic strategies for mesothelioma-involving
markers are likely to be suboptimal. Therefore, we conducted a
systematic review to summarise the literature on the diagnostic
accuracy of serum and cytological markers for the diagnosis of
mesothelioma.
MATERIALS AND METHODS
Search strategy
The systematic search addressed articles with information on
markers in serum and effusions to include or exclude the presence
of mesothelioma published till 31 December 2009. The search was
carried out with Medline and PUBMED (Supplementary Appendix
1 for search strategy). Duplicates from Medline and Embase were
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(Thomson Reuters, New York, NY, USA).
Markers (index tests)
To facilitate the analysis, and to allow a more appropriate
comparison between the studies, we divided the non-invasive
markers into four groups: serum markers; effusion markers, that
is, pleural and peritoneal fluid markers; immunohistochemical
markers used for cytological analysis of effusion samples; and
genetic markers.
Selection
To be eligible for inclusion, studies had to fulfil all of the following
criteria:
1. The study should be an original report in English (i.e., letters,
editorials, case reports, tutorials, reviews, and non-English
studies were excluded).
2. The study should assess the ability of one or more markers to
detect or exclude the presence of mesothelioma, and only
involving non-invasive marker tests. Studies in which marker
tests were assessed in tissue biopsy samples, pelvic washings, or
more than 10% fine-needle aspirates were not included.
3. The diagnosis of mesothelioma had to be confirmed on at least
cytology and/or histology.
4. The study should have a minimal sample size of 10
mesothelioma patients.
5. The study should provide sufficient data to (re)construct a two-
by-two contingency table to estimate the marker’s diagnostic
accuracy.
Studies reporting X10% more specimens than study patients,
indicating that more than one specimen per patient was used, were
excluded. Furthermore, studies investigating markers in high-risk
study populations for screening or surveillance purposes were
excluded.
The article selection was performed in two consecutive phases:
title and abstract assessment (one reviewer, SB) and full-article
assessment (two independent reviewers, SB and ES).
Data extraction
If a study was included, the two reviewers independently extracted
the following elements from the article: overall study characteristics,
for example, author(s), institution, date of publication, recruitment
setting, study design and study years; participant characteristics, for
example, description of the mesothelioma patients and comparison
group; details of the index marker test including the positive vs
negative cut-off value; and type of reference test used to confirm the
presence or absence of mesothelioma.
The number of true positives (TP), false positives (FP), true
negatives (TN) and false negatives (FN) were extracted and used to
construct a two-by-two table, if possible, separately for each
comparison group. Comparison groups were summarised to either
other malignancies or no malignancies, which could include also
healthy participants. If more than one cut-off value was used, we
selected the value closest to the cut-off corresponding with 95%
specificity (avoiding FPs as much as possible). For immunohisto-
chemical markers, we selected the value closest to the 10% cut-off
according to the percentage of cells exhibiting staining (as it is a
frequently used value in immunocytology and implies that samples
were considered positive for the marker if at least 10% of
malignant mesothelioma cells were immunohistochemically
stained). Data of the diagnostic value of a combination of markers
were not extracted.
Discrepancies between the two reviewers were resolved by
consensus. If needed, a third and a fourth reviewer (HK, KGMM)
resolved the remaining discrepancies. When studies with over-
lapping data sets were published, preference was given to those
studies, which had the highest number of mesothelioma patients or
used malignancy as a comparison group (which better reflects
clinical practice). If a study evaluated various markers and results
of a subset of these markers were published in a more recent study,
then only the results of the duplicate markers were excluded from
the first study.
Quality assessment
The methodological quality of each included study was indepen-
dently assessed by the two reviewers using the Quadas instrument
(see Supplementary Appendix 2), a widely accepted and validated
tool for the quality assessment of diagnostic accuracy studies in
systematic reviews (Whiting et al, 2003). In case of doubt, a third
or fourth reviewer was consulted (HK and KGMM).
Data synthesis
Results were summarised as per type of marker and as per
comparison group (i.e., other malignancies or no malignancies).
Markers reported in at least six studies were described more
comprehensively. As is common in diagnostic systematic reviews
and meta-analysis, we used sensitivity and specificity as our
primary measures of association. Sensitivity was calculated by
dividing TP by (TPþFN) and specificity by dividing TN by
(FPþTN) from the (re)constructed two-by-two tables. Associated
95% confidence intervals (CIs) were assessed using the Wilson
score method (Newcombe, 1998). To graphically present the
results, estimates of sensitivity and specificity of a single marker
across studies were summarised in a receiver-operating character-
istic (ROC) graph, plotting the markers’ sensitivity on the y axis
against the 1 specificity on the x axis. When different studies on
the same biomarker shows different sensitivity and specificity, it
does not necessarily mean that the results are different or
heterogeneous; they might simply have used a different (explicit
or implicit) cut-off value for marker positivity. As with a change in
cut-off value, the sensitivity and specificity commonly increase or
decrease in opposite directions (negative correlation), the ROC
curve for such marker should show a concave, shoulder-like
pattern. For each marker with different sensitivities and specifi-
cities plotted in ROC space, we quantify whether this could be
explained by such threshold effect by estimating the (negative)
correlation between sensitivity and specificity. This was performed
on the logit scale using the bivariate model (Reitsma et al, 2005).
All analyses were performed in SAS statistical packages, version 9.1
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Search results
Our search provided 1642 hits, of which 307 were eligible for
inclusion, based on title and abstract. After assessment of the
full-text articles, 224 articles were discarded for various reasons
(Figure 1). Thus, this review included 82 articles (see Supplemen-
tary Appendix 3): 36 articles that evaluated serum or effusion
markers, 41 on immunohistochemical markers, 2 studies on
genetic markers, and 3 studies on different types of markers. Most
immunohistochemical studies included epitheloid and biphasic
mesotheliomas.
Study quality
The methodological quality of the studies with focus on the
objective of this review was generally poor and is shown in
Figure 2, with specific details in Table 1 (references to these studies
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sare prefaced by an ‘r’ and listed in Supplementary Appendix 3).
Only three articles were identified that adequately selected a
representative cohort of consecutive patients suspected for
mesothelioma.
r3,r22,r76 Of these, two articles were on the basis of
one prospective French study.
r3,r22 Other studies used a case–
control design (n¼70), or a cohort of patients with pleural
effusions (n¼9). Owing to these designs, nearly all studies (88%)
suffered from the well-described and problematic disease-verifica-
tion bias (Begg and Greenes, 1983; Lijmer et al, 1999; Mol et al,
2003; Whiting et al, 2004; Rutjes et al, 2005; Biesheuvel et al, 2008).
Furthermore, most studies did not have an adequate description of
the patient-selection procedure, characteristics of the study
participants, the reference standard, and the used cut-off value of
the marker. The time between index test (marker) and reference test
as well as the availability of other clinical data (as is commonly
encountered in practice) were also poorly reported. Blinding for the
results of the marker (index test) when interpreting the reference
test (and vice versa) was fulfilled in about 55% of the studies.
Citation reviewed (n=1642)
Medline citations (n=1236)
Embase citations (n=406)
Review or meta-analysis (n=173)
Not an orginal report (case-reports, letters, editorials, tutorials, guidelines or proposal) (n=331)
Not a diagnostic study (n=687)
Not on mesothelioma (n=22)
Not on a marker under study or not assessed in body fluid (n=73)
Non-English (n =49)
Not an original study (n=5)
Not a diagnostic study (n=14)
Not on mesothelioma or number of mesothelioma patients < 10 (n=98)
Not on a marker under study or not assessed in body fluid (n=53)
Results included tissue biopsies or more than 10% fine needle aspirates (n=9) 
Reporting 10% more specimens than study patients (n=3)
Sensitivity and specificity could not be calculated (n=37)
Double publications (n=6)
Studies included in the systematic review (n=82)
Studies retrieved for detailed review (n=307)
Several types of
markers
(n=3)
Serum or effusion
marker
(n=36)
Immunohistochemical
marker
(n=41)
after exclusion of duplicates that were already identified in medline (n=630)
Genetic marker
(n=2)
Figure 1 Flowchart of the selection of the relevant articles. Serum and effusion markers include tests to detect serum and effusion marker levels;
immunohistochemical markers include marker tests used for cytological analysis of effusion samples; genetic markers include polymerase chain reaction tests
to detect specific gene expressions or fluorescence in situ hybridisation (FISH) tests to detect gene deletions with the use of specialised gene probes.
0
(in %)
Representative patient sample
Study participants clearly described
Selection criteria clearly described
Adequate reference standard
Acceptable delay between tests
Partial verification avoided
Differential verification avoided
Incorporation avoided
Adequate index test description 
Cut-off value clearly described
Adequate reference standard description
Blinding for reference test results
Blinding for index test results
Clinical data available as in practice
Uninterpretable test results reported
Yes No Unclear
100 90 80 70 60 50 40 30 20 10
Figure 2 Summary of quality of the included studies according to the Quadas criteria (see Supplementary Appendix).
Markers for diagnosis of mesothelioma
S van der Bij et al
1327
British Journal of Cancer (2011) 104(8), 1325–1333 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTable 1 Study characteristics and quality of included studies (ordered by year of study)
Quality assessment
a
First author-year Study design Index test 1a 1b 2 3 4 5 6 7 8a 8b 9 10 11 12 13
Studying serum or effusion markers
Aleman – 2009
r1 Case–control SMRP
(e) 2 2 113211 1 1 2 1 1 1 1
Davies – 2009
r2 Prospective cohort of consecutive patients with
pleural effusion, suspected of pleural malignancy
SMRP
(e) 2 1 113211 1 1 2 1 1 1 1
Grigoriu – 2009
r3 b
Cohort of patients with suspected mesothelioma HA
(es) 1 1 113111 1 2 1 1 3 1 2
Rodriquez Portal – 2009
r4 Prospective case–control SMRP
(s) 2 1 113211 1 1 2 1 1 1 1
Shigematsu – 2009
r5 Case–control Gene-X
(s), THBS-2
(s) 2 2 213211 1 1 2 1 1 1 1
Amati – 2008
r6 Prospective case–control 80HdG
(s),H G F
(s), PDGFb
(s),S M R P
(s),
VEGFb
(s), bFGF
(s)
2 1 113211 1 2 2 1 1 1 1
Creaney – 2008
r7 Case–control MPF
(s),S M R P
(s), osteopontin
(s) 2 1 213211 1 2 2 1 1 1 2
Iwahori – 2008
r8 Case–control MPF
(s),S M R P
(s) 2 2 213211 1 1 2 1 1 1 1
Pass – 2008
r9 Case–control SMRP
(es) 2 1 213211 1 1 2 1 1 1 2
Schneider – 2008
r10 Prospective case–control SMRP
(s) 2 1 213231 1 1 2 1 3 1 1
Creaney – - 2007
r11 b
Case–control CA125
(s) 2 2 212211 1 1 1 1 1 1 1
Creaney – 2007
r12 c
Retrospective cohort of consecutive patients
with pleural effusion
SMRP
(e) 2 1 113111 1 1 2 1 1 1 2
Cristaudo – 2007
r13 Case–control SMRP
(s) 2 1 213211 1 1 2 1 1 1 1
Di Serio – 2007
r14 Case–control SMRP
(s) 2 1 213231 1 1 2 1 3 1 1
Grigoriu – 2007
r15 b
Case–control Osteopontin
(s) 2 1 113111 1 2 2 1 3 1 2
Shiomi – 2007
r16 Prospective case–control MPF
(s) 2 1 113211 1 1 1 1 1 1 1
Van den Heuvel – 2007
r17 Retrospective case–control CEA
(s), CYFRA21-1
(s),S M R P
(s) 2 1 113211 1 1 2 1 1 1 1
Welker – 2007
r18 Case–control HA
(e) 2 2 223211 1 1 1 1 3 1 1
Onda – 2006
r19 Retrospective case–control MPF
(s) 2 1 213211 1 1 2 1 1 1 1
Filiberti – 2005
r20 Prospective case–control PDGF-AB
(s) 2 1 213211 1 1 1 1 1 1 1
Pass – 2005
r21 Case–control Osteopontin
(s) 2 1 113211 1 1 1 1 1 1 1
Scherpereel – 2005
r22 Prospective cohort of consecutive patients
with suspected or recently diagnosed mesothelioma
SMRP
(es) 1 1 113111 1 1 2 1 3 1 1
Neri – 2003
r23 Prospective case–control p53
(s) 2 1 113111 1 1 2 1 1 1 1
Villena – 2003
r24 Prospective cohort of patients with pleural effusion CA15-3
(e), CA549
(e), CA72-4
(e), CEA
(e) 2 1 113311 1 1 1 1 1 1 1
Creaney - 2001
r25 Case–control p53
(s) 2 2 213211 1 1 2 1 1 1 1
Paganuzzi – 2001
r26 Cohort of consecutive patients with pleural effusion CEA
(e), CYFRA21-1
(e) 2 2 213131 1 1 2 1 3 1 1
Fuhrman – 2000
r27 Prospective case–control CEA
(es),H A
(e) 2 2 213211 1 1 2 1 1 1 2
Alatas – 1999
r28 Case–control CA15-3
(es), CA19-9
(e), CEA
(es),
CYFRA21-1
(es),N S E
(es), TSA
(es)
2 1 213211 1 1 2 1 1 1 1
Miedouge – 1999
r29 Retrospective case–control CA15-3
(e), CA19-9
(e), CA72-4
(e),
CEA
(e), CYFRA21-1
(e),N S E
(e), SCC
(e)
2 2 113231 1 1 1 1 1 1 1
Nisman – 1998
r30 Case–control CEA
(s), CYFRA21-1
(s), TPS
(s) 2 2 213211 1 1 1 1 1 1 1
Atagi – 1997
r31 Prospective cohort of consecutive patients with
pleural effusion or previously diagnosed mesothelioma
CEA
(e),H A
(e) 2 2 113133 1 1 1 1 3 1 2
Ebert – 1997
r32 Prospective case–control CEA
(s), CYFRA21-1
(s),N S E
(s),
TPA-M
(s), TPS
(s)
2 2 213211 1 1 1 1 1 1 2
Shijubo – 1995
r33 Case–control CEA
(e), SP-A
(e) 2 2 213211 1 1 2 1 1 1 1
Villena – 1995
r34 Prospective cohort of patients with pleural effusion CA15-3
(e), CA19-9
(e), CA72-4
(e), CEA
(e) 2 1 113311 1 1 2 1 1 1 1
Whitaker – 1986
r35 Retrospective case–control CEA
(e) 2 2 213211 1 1 1 1 1 1 1
Fravelli – 1984
r36 Cohort of patients with pleural effusion CEA
(e) 2 1 213311 1 1 1 1 1 1 1
Studying immunohistochemical markers
Shen – 2009
r37 Retrospective case–control EMA, Glut-1m, Glut-1p, XIAP 2 2 2 1 3 2 3 3 1 2 2 1 1 3 1
Slipicevic – 2009
r38 Case–control IGF-II, IGFBP3 2 2 2 1 3 2 3 3 1 2 2 3 3 3 1
Yuan – 2009
r39 Case–control B72-3, Ber-EP4, EMA,
Tenascin-X, calretinin
2 2 213211 1 2 2 3 1 3 1
Bhalla – 2007
r40 Retrospective case–control CK5, D2-40, calretinin, podoplanin 2 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Facchetti – 2007
r41 Retrospective cohort of patients with effusion Claudin4 2 2 2 1 3 2 1 1 1 1 1 3 1 3 1
Grefte – 2007
r42 Retrospective case–control B72-3, Ber-EP4, CEA, EMA,
HMFG-2, calretinin
2 2 213233 1 2 2 1 3 2 1
Kleinberg – 2007
r43 Retrospective case–control Claudin1, claudin3 2 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Pu – 2007
r44 Retrospective case–control MOC-31, WT-1, mesothelin, p63 2 2 2 1 3 2 1 1 1 2 2 1 1 3 2
Shield – 2007
r45 Retrospective case–control CK5/6, calretinin 2 2 2 1 3 2 2 3 1 2 1 3 2 3 1
Aerts – 2006
r46 Prospective case–control Ber-EP4, CEA, EMA, TAG-72 2 2 2 1 3 2 3 3 1 2 2 1 3 2 1
Bassarova – 2006
r47 Case–control D2-40 2 2 2 1 3 2 3 3 1 2 2 3 3 3 1
Li – 2006
r48 Retrospective case–control Ber-EP4, CAM5-2, CEA, CK5/6,
K903, calretinin
2 2 213233 1 2 2 3 3 3 1
Saad – 2006
r49 Retrospective case–control CK5/6, D2-40, TTF-1, WT-1,
calretinin, p63
2 2 213231 1 2 1 1 3 2 1
Sivertsen – 2006
r50 Case-control E-cadherin, N-cadherin, P-cadherin 2 2 2 1 3 2 3 3 2 2 2 3 3 3 1
Afify – 2005
r51 Retrospective case–control CD44S, HA 2 2 2 1 3 2 1 1 1 2 1 3 1 3 1
Hecht – 2005
r52 Retrospective case–control MOC-31 2 2 2 2 3 2 1 1 1 2 2 3 1 3 1
Saad – 2005
r53 Retrospective case–control EMA 2 2 2 1 3 2 1 1 1 1 2 1 1 2 1
Saqi – 2005
r54 Case–control CD138 2 2 2 1 3 2 1 1 1 1 2 3 1 3 1
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Supplementary Appendix 4 provides a complete summary of the
performance of all markers, across the included studies. In total, 54
immunohistochemical markers, 21 serum markers, 12 effusion
markers, and 1 genetic marker were identified. The most
frequently evaluated immunohistochemical marker was EMA
followed by BER-EP4, CEA, and calretinin (Supplementary
Appendix 4, Table 2.3). Among serum markers, the most
frequently investigated were SMRP and CEA, (Supplementary
Appendix, Table 2.1) and among effusion markers CEA, CA15-3,
HA, and SMRP (Supplementary Appendix 4, Table 2.2). Results on
genetic markers were sparse (Supplementary Appendix 4, Table
2.4). The number of eligible papers allowed a closer evaluation of
SMRP in serum and CEA in effusion, as well as the immunohis-
tochemical value of CEA, Ber-EP4, calretinin, and EMA.
Figures 3 and 4 show the ROC space plots for the SMRP in
serum and CEA in effusions, and the immunohistochemical
markers Ber-Ep4, CEA, EMA, and calretinin. In Figure 3, their
performance to discriminate mesothelioma from other malignant
diseases is shown, and in Figure 4, the performance to discriminate
mesothelioma from non-malignancies. From these figures a clear
threshold effect seems apparent for SMRP, meaning that the
variation between studies is probably due to differences in the
applied positivity threshold. Studies with a higher threshold mostly
produced higher sensitivities and lower specificities. This finding
is supported by the significant negative correlations between the
logit sensitivity and logit specificity ( 0.95, 95% CI:  0.99 to
 0.27 in Figure 3 and  1.00, 95% CI:  1.00 to  0.99 in Figure 4).
Overall, SMRP levels were lower among sarcomatoid mesothelioma
compared with the other types (data not shown).
In all CEA studies, effusion CEA levels lower than 40ngml
 1
were compatible with both non-malignancy and mesothelioma.
Discrimination between mesothelioma and non-malignancy, based
on CEA levels, was therefore poor (Figure 4). The levels of CEA
among other malignancies were in general higher than in
mesothelioma patients. Figure 3 shows that the specificity of
CEA (i.e., the proportion of patients with other malignant diseases
above a specific cut-off point) varied widely among studies and
ranged from 43 (95% CI: 33–54) to 88% (95% CI: 69–96). These
Table 1 (Continued)
Quality assessment
a
First author-year Study design Index test 1a 1b 2 3 4 5 6 7 8a 8b 9 10 11 12 13
Schonherr – 2004
r55 Case–control Ki67 2 2 2 1 3 2 1 1 1 1 1 3 1 3 1
Afify – 2002
r56 Retrospective case–control TTF-1 2 2 2 1 3 2 1 1 1 2 1 3 1 3 1
Afify – 2002
r57 Retrospective case–control Actin, desmin, myogenin, myoglobin 2 2 2 1 3 2 1 1 1 2 1 3 1 3 1
Davidson – 2001
r58 b
Case–control CA125, CEA, desmin, p53, vimentin 2 2 2 1 3 2 1 2 1 2 1 1 2 1 1
Hecht – 2001
r59 Retrospective case–control WT1 2 2 2 1 3 2 3 3 1 2 2 3 3 3 1
Hecht – 2001
r60 Retrospective case–control TTF-1 2 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Simsir – 2001
r61 Retrospective case–control SV-40 2 2 2 3 2 2 1 1 1 2 2 3 1 3 1
Wieczorek – 2000
r62 Retrospective case–control Calretinin 2 2 2 1 3 2 1 1 1 1 1 1 1 2 1
Dejmek – 1999
r63 Retrospective case–control CAM5-2, Leu-M1 2 2 2 1 3 2 2 3 1 2 2 3 3 3 2
Motherby – 1999
r64 Retrospective cohort of patient
with pleural effusion
Ber-EP4, CEA, EMA, Leu-M1 2 2 2 3 3 2 2 2 1 2 2 3 2 3 2
Simir – 1999
r65 Retrospective case–control E-cadherin, N-cadherin, calretinin 2 2 2 3 3 2 1 1 1 2 2 3 1 3 1
Ascoli – 1997
r66 Case–control HBME-1 2 2 2 1 3 2 2 3 1 2 1 3 3 3 1
Delahaye – 1997
r67 Case–control B72-3, Ber-EP4, CEA, Leu-M1, MOC-31 2 2 2 1 3 2 3 3 1 2 2 3 3 3 1
Ascoli – 1995
r68 Case–control Ber-EP4, EMA, cytokeratin,
thrombomodulin
2 2 213223 1 2 1 3 3 3 1
Baars – 1994
r69 Retrospective case–control Keratin7 2 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Donna – 1992
r70 Case–control Mesothelin 2 2 2 1 3 2 2 1 1 1 2 3 3 3 1
Betta – 1991
r71 Case–control B72-3 2 2 2 1 3 2 3 1 1 2 2 3 3 3 1
Delahaye – 1991
r72 b
Retrospective case–control EMA, OV632 2 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Kuhlman – 1991
r73 Retrospective case–control B72-3, BMA-120, Ber-EP4, CEA,
HEA-125, cytokeratin, vimentin
2 2 213211 1 2 2 3 1 3 1
Linari – 1989
r74 Prospective case–control HMFG-2 2 2 2 3 3 2 2 3 1 2 2 3 2 3 1
Cibas – 1987
r75 Retrospective case–control CEA, EMA, HMFG-2, keratin 2 1 2 1 3 2 1 1 1 2 2 3 1 3 1
Ghosh – 1987
r76 Retrospective cohort of patients with
suspected/diagnosed mesothelioma
CA1/2, CEA, HMFG-2 1 2 2 1 3 2 1 1 1 2 2 3 1 3 1
Walts – 1983
r77 Retrospective case–control Keratin 2 2 2 1 3 2 3 1 1 2 1 3 3 3 1
Studying genetic markers
Illei – 2003
r78 Prospective case–control CDKN2A-deletion
(e) 2 1 213231 1 1 2 3 3 3 1
Flores-Staino – 2009
r79 Case–control CDKN2A-deletion
(e) 2 2 213211 1 1 2 3 1 3 1
Studying several types of markers
Botelho – 2008
r80 Retrospective case–control Genetic: CDKN2A-deletion
(e)
immunohistochemical: Ber-EP4, calretinin
2 2 223221 1 2 2 3 2 3 1
Creaney – 2008
r81 Retrospective case–control Biomarkers: CA15-3
(es)
immunohistochemical: EMA
2 2 213233 1 1 2 3 3 3 2
Dejmek – 2005
r82 Case–control Biomarkers: HA
(e)
immunohistochemical: Ber-EP4, CEA,
Ca125, EMA, HBME-1, Sial-Tn,
thrombomodulin, vimentin
2 2 213221 1 1 2 3 3 3 2
(e), assessed in effusion;
(s), assessed in serum;
(es), assessed in effusion and serum.
aSee Supplementary Appendix for criteria on quality assessment, items were scored 1¼yes,
2¼no, 3¼unclear.
bAlso studied other markers that we did not incorporate because of overlap with other studies.
cAlso studied SMRP in serum that we did not incorporate
because of overlap with other studies.
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sdifferences could only partly be explained by differences in the
applied cut-off value (correlation was not significant), and by the
type of other malignancies included in the control group.
The immunohistochemical markers Ber-EP4, CEA, and calreti-
nin can be useful in discriminating mesothelioma from other
malignant diseases (Figure 3), whereas EMA can be useful in dis-
criminating mesothelioma from non-malignant diseases (Figure 4).
Specificity of Ber-Ep4 and CEA was more heterogeneous than
sensitivity and sensitivity was, in general, high (Figure 3). For
calretinin, the sensitivity ranged from 85 to 100%, except for the
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Figure 3 Sensitivity against 1-specificity in ROC space to discriminate mesothelioma from other malignant diseases. The height of the blocks is
proportional to the reciprocal of the number of mesothelioma patients (mesothelioma yes subjects) and the width of the blocks is proportional to the
reciprocal of the number of patients with other malignant diseases (mesothelioma no subjects).
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Figure 4 Sensitivity against 1-specificity in ROC space to discriminate mesothelioma from non-malignancy. The height of the blocks is proportional to the
reciprocal of the number of mesothelioma patients (mesothelioma yes subjects) and the width of the blocks is proportional to the reciprocal of the number
of non-malignant patients (mesothelioma no subjects).
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sstudy of Simsir et al
r61. In that study
r65 calretinin staining was
much lower among mesothelioma and benign samples.
The immunohistochemical marker EMA had a positive cyto-
plasmic or membranous staining in the majority of the papers,
ranging from 73 to 100% among mesothelioma patients and from
91 to 100% among other malignant diseases. Four stu-
dies
r39,r42,r75,r82 made a distinction in staining pattern as well,
showing that a membranous staining EMA pattern was mainly
observed in mesothelioma patients (55–92%) and not in other
malignant diseases (o20%) (Supplementary Appendix 4, Table
2.3). Discriminating mesothelioma from non-malignant diseases
based on EMA provided high sensitivity and specificity (Figure 4).
For EMA the correlation between logit sensitivity and specificity
was nonsignificant in Figure 4 ( 0.56 (95% CI:  0.92 to –0.30)).
Direct marker comparisons
Some of the studies evaluated multiple markers on the same
patients. Two studies
r42,r48 evaluated both the accuracy of
calretinin and CEA. To discriminate mesothelioma from other
malignant diseases, both the studies showed that specificity was
higher for calretinin (in both studies: 100%) compared with CEA
(in both about 58%). Corresponding sensitivities were 91 and
100% for calretinin and 100% (in both studies) for CEA.
Three studies
r39,r48,r80 in which calretinin and Ber-Ep4 were
assessed showed that calretinin was a better discriminator than
Ber-EP4, whereas one other study
r42 showed a similar perfor-
mance of both markers.
Seven other studies directly compared the immunohistochem-
ical markers CEA and Ber-EP4.
r46,r48,r64,r67,r73,r82 Sensitivity values
were highest for CEA, and in five of the seven studies
r42,r46,r64,r67,r73
Ber-Ep4 provided the highest specificity.
No robust conclusion could be drawn on the relative
performance of markers across comparative studies because of
large differences in study methods and heterogeneity of the results
(Table 1, Supplementary Appendix 4, Table 2.3).
DISCUSSION
We systematically reviewed all available evidence on the diagnostic
performance of markers in serum, pleural fluid, and ascites,
used to non-invasively discriminate mesothelioma from non-
mesothelioma disorders. Numerous markers have been assessed.
SMRP, CEA, Ber-EP4, calretinin, and EMA were studied most
frequently. We found that the majority of studies had an
exploratory design and as such showed a rather poor reporting
and low quality as scored by the Quadas instrument for assessing
methodological quality of individual studies in diagnostic reviews.
Nevertheless, despite this, our analyses indicate that the most
valuable markers appear to be CEA, Ber-EP4, and calretinin to
discriminate mesothelioma from other malignant diseases. The
markers EMA and SMRP were most valuable in discriminating
mesothelioma from non-malignant diseases. None of the markers
performed well to differentiate mesothelioma from all other
diseases.
Furthermore, all the immunohistochemical markers, especially
CEA, are of value in exclusion of mesothelioma as sensitivity was
in general high. So, positive staining for CEA and Ber-EP4 and
negative staining for EMA and calretinin are reassuring that a
patient does not have mesothelioma. The specificity of these
markers varied and depended on the comparison group and
therefore the differential diagnosis. The marker SMRP might be of
value confirming the diagnosis mesothelioma when a high cut-off-
value is applied (resulting in high specificity).
Our data involved the markers used for cytological examination
of pleural fluid and ascites, as well as markers used to test serum,
and pleural fluid and ascites levels. To our knowledge, no
comprehensive systematic literature search on immunohistochem-
ical markers in the cytological diagnosis of mesothelioma has been
performed previous to this study. Recently, a meta-analysis was
published on the diagnostic performance of serum SMRP only
(Luo et al, 2010). Notwithstanding large differences in the methods
of data extraction, the inferences of that review were consistent
with ours. Still, we come to another conclusion about the study
quality. Other meta-analyses on effusion markers focused on
differentiating benign from malignant diseases in general, and as
such are not directly comparable with our review as our focus was
to quantify the diagnostic accuracy of these markers for
discriminating mesothelioma from non-mesothelioma (Liang
et al, 2008; Shi et al, 2008). Other reviews in this field did not at
all perform a systematic search, and might, thus, be liable to
selection bias in terms of included studies (Scherpereel and Lee,
2007; Greillier et al, 2008; Creaney and Robinson, 2009).
To appreciate this systematic review, various issues should be
addressed. First, the rather low quality of the eligible studies limits
the conclusions about the value of markers in the diagnosis of
mesothelioma. Therefore, conform to prevailing guidelines of
diagnostic meta-analyses, we explicitly refrained to meta-analyse
or pool the sensitivities and specificities of the individual markers.
The low quality might be partly explained by including all studies
with information on markers for mesothelioma, regardless of their
main objective. The design of most studies was exploratory, rather
than confirmatory, which is illustrated by the fact that 88 markers
were studies in the 82 selected papers. Exclusion of all studies with
low-quality scores on the Quadas instrument would have
interfered with our main objective to obtain a complete overview
of markers, and was therefore not performed. Furthermore, just a
few studies had an acceptable quality, and only two studies had a
prospective selection of consecutive patients suspected of
mesothelioma. Several other studies used a prospective, consecu-
tive patient inclusion, but selected patients on grounds of the
presence of pleural effusion, rather than on the initial suspicion of
mesothelioma.
r2,r31,r34 Once pleural effusion is confirmed by
imaging, only those patients that are still suspected of mesothe-
lioma after imaging are warranted for further testing for
mesothelioma. The most frequently applied design was the case–
control design, in a retrospective manner. This design has been
criticised for leading to biased estimates of accuracy (Lijmer et al,
1999; Mol et al, 2003; Whiting et al, 2003, 2004; Rutjes et al, 2005;
Biesheuvel et al, 2008). Owing to this high number of case–control
studies, we could not validly combine ‘benign and other malignant
diseases’ into one control group. Otherwise, overall sensitivity and
specificity would have been strongly depended on the distribution
of other malignant and non-malignant diseases, included in these
studies.
Second, reporting of study details was also poor. For example,
some studies explicitly stated that they excluded paucicellular
cytological samples, whereas the majority of studies provided no
details about which types of other malignant or non-malignant
cases were included in the control subjects. Owing to the low
quality and poor reporting of study details, we could also not
explore study heterogeneity.
Third, we did not assess the diagnostic value of combined
markers but focused on the value of single markers instead.
Pathological examination of effusion includes the use of several
immunohistochemical markers. However, as studies used different
combinations of markers we did not have sufficient studies to
properly meta-analyse their diagnostic accuracy. Nevertheless,
knowledge of the value of individual markers will certainly add to
the performance of combined marker sets.
Fourth, we did not search for non-published studies because of
the large number of studies identified. Hence, our results may
suffer from publication bias. Also, studies, which did not report
proportions of patients above or below a certain cut-off value
could not be included in our analysis as no two-by-two table could
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difference in mean or median marker levels among groups.
Finally, head-to-head comparisons are preferred to meta-
analytically compare the diagnostic accuracy of markers. Although
sufficient studies were performed to evaluate both CEA and
Ber-Ep4, no robust conclusion could be drawn on their relative
performance because of the heterogeneity of the studies.
Having raised these concerns, the question remains which
markers are most suitable for use in clinical practice. The aim of
developing serum and cytological markers is to establish a non-
invasive diagnosis of mesothelioma to prevent the already
weakened patient undergoing invasive tests. In addition, the
diagnosis of mesothelioma should be firm to enable a financial
compensation, requiring markers to have high specificity. A major
advantage of SMRP is that it can be applied by the patient’s
physician, whereas the use of cytological immunohistochemical
markers is reserved for a pathologist. Unfortunately, the diagnostic
performance of SMRP alone seems not (yet) high enough for that
purpose. The specificity of cytological markers (CEA, Ber-EP4,
calretinin) appears to be rather heterogeneous, potentially, because
of differences in study quality, marker handling, type of antibody,
type of effusion, and patient and sample selection among studies.
The immunohistochemical marker EMA will only provide a high
specificity when the differential diagnosis is between mesothelioma
and reactive mesothelial proliferation. However, the EMA marker
was not always 100% specific across the studies. Moreover, the
value of markers, in particular immunohistochemical markers,
depends on the type of mesothelioma. Sarcomatoid mesothelioma,
which accounts for about 15% of all mesotheliomas, shed almost
no malignant cells into the fluid-making markers less useful
(Husain et al, 2009). Most immunohistochemical studies that we
scrutinised included only epitheloid and biphasic mesotheliomas.
Furthermore, morphology has a major role in the decision-making
process when evaluating cytological samples. Unfortunately, the
majority of the studies did not consider the (added) value of
immunohistochemical staining in relation to morphology.
To date, the vast majority of the studies on mesothelioma
markers seem to involve rather early-phase diagnostic studies
(using retrospective, case–control type of designs) (Fryback and
Thornbury, 1991; Lijmer et al, 2009). It seems that the next step in
studying the most promising markers, is the conduction of
prospective accuracy studies in the proper target population, that
is, patients selected on their suspicion of having mesothelioma,
rather than on its true presence or absence (Rutjes et al, 2005;
Biesheuvel et al, 2008). Subsequently, the incremental marker
value of these markers beyond existing diagnostics such as
patient characteristics and previous clinical tests, should be
investigated (Riley et al, 2009; Moons, 2010). Indeed, these
prospective studies are extremely hard to perform by single
institutions if the disease under study has incidences as low as that
of mesothelioma. Hence, we encourage researchers and physicians
to join forces to enhance the proper quantification of the
diagnostic accuracy of the most promising markers for mesothe-
lioma. Alternatively, retrospective nested case–control studies
could be conducted, which are especially efficient for rare diseases
and if human material is stored (Rutjes et al, 2005; Biesheuvel et al,
2008; Moons, 2010). In these studies both cases and controls can be
sampled from a single-source population, typically defined by the
initial presentation or suspicion of the patient. This systematic
review indicated that promising markers that certainly allow for
further validation are SMRP, CEA, EMA, calretinin, and Ber-Ep4.
In addition, other markers might be promising, which have not yet
been validated in a number of studies, for example TTF-1. Finally,
we encourage the improvement of reporting of diagnostic accuracy
studies, following the STARD guidelines (Bossuyt et al, 2003a,b).
Only accurate quantification and reporting of the (added) value of
mesothelioma markers will lead to the clinical use of the
appropriate markers.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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